Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 14;40(13):1428–1438. doi: 10.1200/JCO.21.01601

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — (A) Kaplan-Meier estimates of investigator-assessed PFS in the intention-to-treat population and (B) analysis of PFS in predetermined prognostic subgroups. (A) The log-rank P value of .042 is one-sided and thus not significant. (B) P values are two-sided for treatment by subgroup interaction. ^aBRAF V600 mutation as determined by local testing. AJCC 7, American Joint Committee on Cancer's Cancer Staging Manual, 7th edition; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase; mut/Mb, mutations per megabase; PD-L1, programmed death ligand 1; PFS, progression-free survival; placebo-DabTram, placebo plus dabrafenib and trametinib; sparta-DabTram, spartalizumab plus dabrafenib and trametinib; TMB, tumor mutational burden; ULN, upper limit of normal.